Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Rituximab
 More »

  • Pharma Touting Phase II/III Wins in Run-Up to ASCO
    ... idelalisib in combination with rituximab for older patients with treatment-naïve CLL. Gilead said patients treated with the idelalisib-rituximab combination achieve a complete ...
    5-16-2013
  • Lilly Halts Development of Lymphoma Drug After Phase III Failure
    Enzastaurin failed to show a statistically significant increase compared to placebo in disease-free survival in patients at high risk of DLBCL relapse following rituximab-based ...
    5-10-2013
  • Biosimilars: 10 Drugs to Watch
    ... announcing plans August 2011 to collaborate on biosimilars for trastuzumab and rituximab. ... and 2018 in U.S. Rituxan / MabThera (rituximab) Drug developers: Amgen: Biosimilar in ...
    4-22-2013
  • Pharmacyclics Achieves Another $50M Milestone
    trial (CLL3001) of ibrutinib (PCI-32765) in combination with bendamustine and rituximab in patients with relapsed or refractory CLL/SLL enrolled its fifth patient in ...
    4-11-2013
  • Electronics Giants Set Sights on Biotech
    ... Last October, the company halted development of a biosimilar version of the Roche/Biogen Idec lymphoma and rheumatoid arthritis drug Rituxan (rituximab)-just six months after ...
    4-1-2013
  • Biosimilars: Not So Far So Fast
    (through its joint venture with Lonza) is evaluating the path forward for rituximab." ... competition, suggesting biosimilar rituximab could enter the market in 2016. This ...
    3-15-2013
  • Top 20 Best-Selling Drugs of 2012
    ... 22.6% at CER from $1.413 billion (€1.054 billion) in 4Q 2011 at CER 5 #5. Rituxan (rituximab, MabThera) Drug maker: Roche Indication(s): Non-Hodgkin's lymphoma, chronic ...
    3-1-2013
  • Optimizing the Quality and Accuracy of Biopharmaceutical Analysis...
    Kimzey will discuss assessing variability of an innovator glycan profile for development of a biosimilar. He will present rituximab and bevacizumab glycan profile data generated ...
    2-19-2013
  • Bittersweet News at Biogen Idec
    Avonex (interferon beta-1a) for relapsing forms of MS. The drug generated $753.2 million in Q4, up 7% from $703.2 million. Rituxan (rituximab) revenue from an unconsolidated joint ...
    1-28-2013
  • Where Downstream Operations Are Headed
    it is a very competitive marketplace, and Teva and Lonza have already halted their rituximab biosimilar development, so looking at areas such as cost reductions in manufacturing ...
    1-1-2013
  • New Method for "Fingerprinting" Biosimilars
    ... Kits are currently offered for seven of the most popular mAb-based innovator biologics (Rituximab, Trastuzumab, Bevacizumab, Adalimumab, Cetuximab, Alemtuzumab, and Palivuzumab, as ...
    10-15-2012
  • BioLineRx Nabs Phase II-Ready AML Candidate
    In vivo studies have also demonstrated that BL-8040 is effective both alone and in combination with rituximab in reducing bone marrow metastasis of lymphoma cells and stimulating ...
    9-4-2012
  • Autologous Immunotherapy Updates at ASCO Further Define Antitumor...
    Biovest and NCI-sponsored investigators reported clinical and immunologic findings from an 11-year follow-up of 26 MCL patients treated with BiovaxID following DA-EPOCH-Rituximab. ...
    6-1-2012
  • Reducing Uncertainty Surrounding Biosimilar Production
    ... Sandoz' work with rituximab is a good example, notes Dr. Windisch. Rituximab works largely by inducing ADCC (antibody-dependent cell-mediated cytotoxicity), which in turn is ...
    5-15-2012
  • EC Conditionally Approves Cell Therapeutics' Pixantrone for Non...
    PIX306, which is comparing Pixuvri-rituximab to gemcitabine-rituximab in relapsed patients with aggressive B-cell NHL who aren't eligible for autologous stem cell transplantation. ...
    5-11-2012
  • More »

    Journal Articles

  • Current and Future Role of Interferon Beta in the Therapy of...
    Rachel A. Farrell, Gavin Giovannoni
    Journal of Interferon & Cytokine Research
    the pipeline, namely, the monoclonal antibodies alemtuzumab, rituximab, and daclizumab and the promising oral agents BG00012, cladribine, fingolimod, laquinimod, and teriflunomide. ...
  • Conservative Management in Primary Vaginal Lymphoma: Role of...
    Aymen Lagha, Sarra Krimi, Nesrine Chraiet, Mouna Ayadi, Hela Rifi, Henda Raies, Amel Mezlini
    Journal of Gynecologic Surgery
    Case: A 34-year-old female patient with a primary vaginal NHL stage IE, with diffuse large-cell B lineage, had an excellent response to cytotoxic chemotherapy (rituximab, ...
  • Association Between -174 Interleukin-6 Gene Polymorphism and...
    Gema Robledo, Cristina Lucía Dávila-Fajardo, Ana Márquez, Norberto Ortego-Centeno, José Luis Callejas Rubio, Enrique de Ramón Garrido, Julio Sánchez-Román, Francisco J. García-Hernández, Raquel Ríos-Fernández, Maria Francisca González-Escribano, Maria Teresa Camps García, Maria Jesús Castillo Palma, Maria del Mar Ayala, Javier Martín, Julio Sanchez-Román, Mª Francisca González-Escribano, Mª Teresa Camps García, Mª Jesús Castillo Palma, Mª del Mar Ayala
    DNA and Cell Biology
    Association Between -174 Interleukin-6 Gene Polymorphism and Biological Response to Rituximab in Several Systemic Autoimmune Diseases DNA and Cell Biology Rituximab has become a ...
  • Cancer Immunotherapy
    Robert O. Dillman
    Cancer Biotherapy and Radiopharmaceuticals
    These include the nonspecific immune stimulants BCG and levamisole; the cytokines interferon-a and interleukin-2; the monoclonal antibodies rituximab, ofatumumab, alemtuzumab, ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll